nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—CYP1A2—type 2 diabetes mellitus	0.381	1	CbGaD
Pentoxifylline—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.031	0.329	CbGbCtD
Pentoxifylline—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0244	0.259	CbGbCtD
Pentoxifylline—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.023	0.245	CbGbCtD
Pentoxifylline—NT5E—brown adipose tissue—type 2 diabetes mellitus	0.0168	0.2	CbGeAlD
Pentoxifylline—CYP1A2—Losartan—type 2 diabetes mellitus	0.0157	0.167	CbGbCtD
Pentoxifylline—PDE5A—penis—type 2 diabetes mellitus	0.0104	0.123	CbGeAlD
Pentoxifylline—PDE5A—artery—type 2 diabetes mellitus	0.00479	0.057	CbGeAlD
Pentoxifylline—ADORA1—nerve—type 2 diabetes mellitus	0.00451	0.0536	CbGeAlD
Pentoxifylline—PDE5A—endothelium—type 2 diabetes mellitus	0.00405	0.0482	CbGeAlD
Pentoxifylline—NT5E—retina—type 2 diabetes mellitus	0.00303	0.0361	CbGeAlD
Pentoxifylline—NT5E—nephron tubule—type 2 diabetes mellitus	0.00286	0.034	CbGeAlD
Pentoxifylline—NT5E—cardiovascular system—type 2 diabetes mellitus	0.00257	0.0305	CbGeAlD
Pentoxifylline—NT5E—kidney—type 2 diabetes mellitus	0.00251	0.0299	CbGeAlD
Pentoxifylline—NT5E—pancreas—type 2 diabetes mellitus	0.00249	0.0297	CbGeAlD
Pentoxifylline—NT5E—cortex of kidney—type 2 diabetes mellitus	0.00244	0.0291	CbGeAlD
Pentoxifylline—NT5E—adipose tissue—type 2 diabetes mellitus	0.00226	0.0269	CbGeAlD
Pentoxifylline—PDE5A—retina—type 2 diabetes mellitus	0.00197	0.0234	CbGeAlD
Pentoxifylline—ADORA2B—adipose tissue—type 2 diabetes mellitus	0.00194	0.0231	CbGeAlD
Pentoxifylline—ADORA2A—cardiovascular system—type 2 diabetes mellitus	0.00183	0.0218	CbGeAlD
Pentoxifylline—PDE4A—adipose tissue—type 2 diabetes mellitus	0.00173	0.0206	CbGeAlD
Pentoxifylline—PDE5A—cardiovascular system—type 2 diabetes mellitus	0.00167	0.0198	CbGeAlD
Pentoxifylline—PDE4B—islet of Langerhans—type 2 diabetes mellitus	0.00161	0.0192	CbGeAlD
Pentoxifylline—NT5E—liver—type 2 diabetes mellitus	0.00159	0.0189	CbGeAlD
Pentoxifylline—ADORA1—cardiovascular system—type 2 diabetes mellitus	0.00158	0.0188	CbGeAlD
Pentoxifylline—ADORA1—kidney—type 2 diabetes mellitus	0.00154	0.0184	CbGeAlD
Pentoxifylline—ADORA1—cortex of kidney—type 2 diabetes mellitus	0.0015	0.0179	CbGeAlD
Pentoxifylline—PDE5A—adipose tissue—type 2 diabetes mellitus	0.00147	0.0175	CbGeAlD
Pentoxifylline—ADORA1—adipose tissue—type 2 diabetes mellitus	0.00139	0.0166	CbGeAlD
Pentoxifylline—PDE4B—pancreas—type 2 diabetes mellitus	0.00113	0.0135	CbGeAlD
Pentoxifylline—ADORA2A—liver—type 2 diabetes mellitus	0.00113	0.0135	CbGeAlD
Pentoxifylline—Theobromine—CYP2E1—type 2 diabetes mellitus	0.00111	0.305	CrCbGaD
Pentoxifylline—PDE4B—cortex of kidney—type 2 diabetes mellitus	0.00111	0.0132	CbGeAlD
Pentoxifylline—Theobromine—CYP1A2—type 2 diabetes mellitus	0.00106	0.29	CrCbGaD
Pentoxifylline—PDE4B—adipose tissue—type 2 diabetes mellitus	0.00103	0.0123	CbGeAlD
Pentoxifylline—PDE4B—liver—type 2 diabetes mellitus	0.000722	0.00859	CbGeAlD
Pentoxifylline—Caffeine—CYP2E1—type 2 diabetes mellitus	0.000572	0.157	CrCbGaD
Pentoxifylline—Caffeine—CYP1A2—type 2 diabetes mellitus	0.000545	0.149	CrCbGaD
Pentoxifylline—CYP1A2—liver—type 2 diabetes mellitus	0.000444	0.00528	CbGeAlD
Pentoxifylline—Caffeine—CYP3A4—type 2 diabetes mellitus	0.00036	0.0988	CrCbGaD
Pentoxifylline—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000206	0.000732	CcSEcCtD
Pentoxifylline—Discomfort—Metformin—type 2 diabetes mellitus	0.000205	0.000729	CcSEcCtD
Pentoxifylline—Nausea—Glipizide—type 2 diabetes mellitus	0.000204	0.000727	CcSEcCtD
Pentoxifylline—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000204	0.000726	CcSEcCtD
Pentoxifylline—Hypotension—Valsartan—type 2 diabetes mellitus	0.000204	0.000726	CcSEcCtD
Pentoxifylline—Vision blurred—Losartan—type 2 diabetes mellitus	0.000204	0.000725	CcSEcCtD
Pentoxifylline—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000204	0.000724	CcSEcCtD
Pentoxifylline—Constipation—Gliclazide—type 2 diabetes mellitus	0.000203	0.000723	CcSEcCtD
Pentoxifylline—Tremor—Losartan—type 2 diabetes mellitus	0.000203	0.000721	CcSEcCtD
Pentoxifylline—Rash—Glimepiride—type 2 diabetes mellitus	0.000203	0.00072	CcSEcCtD
Pentoxifylline—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000202	0.000719	CcSEcCtD
Pentoxifylline—Rash—Sitagliptin—type 2 diabetes mellitus	0.000202	0.000718	CcSEcCtD
Pentoxifylline—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000202	0.000717	CcSEcCtD
Pentoxifylline—Headache—Glimepiride—type 2 diabetes mellitus	0.000201	0.000715	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000201	0.000714	CcSEcCtD
Pentoxifylline—Headache—Sitagliptin—type 2 diabetes mellitus	0.000201	0.000713	CcSEcCtD
Pentoxifylline—Anaemia—Losartan—type 2 diabetes mellitus	0.0002	0.000711	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000199	0.000708	CcSEcCtD
Pentoxifylline—Agitation—Losartan—type 2 diabetes mellitus	0.000199	0.000707	CcSEcCtD
Pentoxifylline—Oedema—Metformin—type 2 diabetes mellitus	0.000199	0.000707	CcSEcCtD
Pentoxifylline—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000199	0.000706	CcSEcCtD
Pentoxifylline—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000198	0.000705	CcSEcCtD
Pentoxifylline—Flushing—Ramipril—type 2 diabetes mellitus	0.000198	0.000704	CcSEcCtD
Pentoxifylline—Angioedema—Losartan—type 2 diabetes mellitus	0.000198	0.000703	CcSEcCtD
Pentoxifylline—Infection—Metformin—type 2 diabetes mellitus	0.000198	0.000703	CcSEcCtD
Pentoxifylline—Insomnia—Valsartan—type 2 diabetes mellitus	0.000198	0.000703	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000197	0.000699	CcSEcCtD
Pentoxifylline—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000196	0.000697	CcSEcCtD
Pentoxifylline—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000196	0.000696	CcSEcCtD
Pentoxifylline—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000196	0.000696	CcSEcCtD
Pentoxifylline—Shock—Metformin—type 2 diabetes mellitus	0.000196	0.000696	CcSEcCtD
Pentoxifylline—Insomnia—Orlistat—type 2 diabetes mellitus	0.000195	0.000694	CcSEcCtD
Pentoxifylline—Malaise—Losartan—type 2 diabetes mellitus	0.000195	0.000694	CcSEcCtD
Pentoxifylline—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000195	0.000694	CcSEcCtD
Pentoxifylline—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000195	0.000694	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000195	0.000693	CcSEcCtD
Pentoxifylline—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000195	0.000692	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000195	0.000692	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000195	0.000691	CcSEcCtD
Pentoxifylline—Somnolence—Valsartan—type 2 diabetes mellitus	0.000194	0.000691	CcSEcCtD
Pentoxifylline—Leukopenia—Losartan—type 2 diabetes mellitus	0.000194	0.000689	CcSEcCtD
Pentoxifylline—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000194	0.000688	CcSEcCtD
Pentoxifylline—Skin disorder—Metformin—type 2 diabetes mellitus	0.000193	0.000687	CcSEcCtD
Pentoxifylline—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000193	0.000685	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000192	0.000684	CcSEcCtD
Pentoxifylline—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000192	0.000684	CcSEcCtD
Pentoxifylline—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000192	0.000681	CcSEcCtD
Pentoxifylline—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000192	0.000681	CcSEcCtD
Pentoxifylline—Palpitations—Losartan—type 2 diabetes mellitus	0.000191	0.00068	CcSEcCtD
Pentoxifylline—Nausea—Glimepiride—type 2 diabetes mellitus	0.000191	0.000678	CcSEcCtD
Pentoxifylline—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000191	0.000677	CcSEcCtD
Pentoxifylline—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00019	0.000676	CcSEcCtD
Pentoxifylline—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.00019	0.000676	CcSEcCtD
Pentoxifylline—Asthenia—Glyburide—type 2 diabetes mellitus	0.00019	0.000676	CcSEcCtD
Pentoxifylline—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.00019	0.000675	CcSEcCtD
Pentoxifylline—Anorexia—Metformin—type 2 diabetes mellitus	0.00019	0.000674	CcSEcCtD
Pentoxifylline—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000189	0.000672	CcSEcCtD
Pentoxifylline—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000188	0.000668	CcSEcCtD
Pentoxifylline—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000188	0.000668	CcSEcCtD
Pentoxifylline—Oedema—Irbesartan—type 2 diabetes mellitus	0.000188	0.000668	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000188	0.000668	CcSEcCtD
Pentoxifylline—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000188	0.000667	CcSEcCtD
Pentoxifylline—Pruritus—Glyburide—type 2 diabetes mellitus	0.000187	0.000666	CcSEcCtD
Pentoxifylline—Constipation—Valsartan—type 2 diabetes mellitus	0.000187	0.000664	CcSEcCtD
Pentoxifylline—Infection—Irbesartan—type 2 diabetes mellitus	0.000187	0.000663	CcSEcCtD
Pentoxifylline—Hypotension—Metformin—type 2 diabetes mellitus	0.000186	0.000661	CcSEcCtD
Pentoxifylline—Erythema—Ramipril—type 2 diabetes mellitus	0.000186	0.00066	CcSEcCtD
Pentoxifylline—Shock—Irbesartan—type 2 diabetes mellitus	0.000185	0.000657	CcSEcCtD
Pentoxifylline—Chest pain—Losartan—type 2 diabetes mellitus	0.000184	0.000655	CcSEcCtD
Pentoxifylline—Myalgia—Losartan—type 2 diabetes mellitus	0.000184	0.000655	CcSEcCtD
Pentoxifylline—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000184	0.000655	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000184	0.000654	CcSEcCtD
Pentoxifylline—Anxiety—Losartan—type 2 diabetes mellitus	0.000184	0.000653	CcSEcCtD
Pentoxifylline—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000183	0.000651	CcSEcCtD
Pentoxifylline—Rash—Bromocriptine—type 2 diabetes mellitus	0.000183	0.000649	CcSEcCtD
Pentoxifylline—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000183	0.000649	CcSEcCtD
Pentoxifylline—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000182	0.000648	CcSEcCtD
Pentoxifylline—Tension—Ramipril—type 2 diabetes mellitus	0.000182	0.000648	CcSEcCtD
Pentoxifylline—Discomfort—Losartan—type 2 diabetes mellitus	0.000182	0.000647	CcSEcCtD
Pentoxifylline—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000182	0.000646	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000182	0.000645	CcSEcCtD
Pentoxifylline—Headache—Bromocriptine—type 2 diabetes mellitus	0.000182	0.000645	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000181	0.000644	CcSEcCtD
Pentoxifylline—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000181	0.000644	CcSEcCtD
Pentoxifylline—Nervousness—Ramipril—type 2 diabetes mellitus	0.00018	0.000641	CcSEcCtD
Pentoxifylline—Dry mouth—Losartan—type 2 diabetes mellitus	0.00018	0.000641	CcSEcCtD
Pentoxifylline—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000179	0.000636	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000179	0.000635	CcSEcCtD
Pentoxifylline—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000179	0.000635	CcSEcCtD
Pentoxifylline—Confusional state—Losartan—type 2 diabetes mellitus	0.000178	0.000633	CcSEcCtD
Pentoxifylline—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000178	0.000632	CcSEcCtD
Pentoxifylline—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000177	0.000631	CcSEcCtD
Pentoxifylline—Somnolence—Metformin—type 2 diabetes mellitus	0.000177	0.000629	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000177	0.000628	CcSEcCtD
Pentoxifylline—Oedema—Losartan—type 2 diabetes mellitus	0.000177	0.000628	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000177	0.000628	CcSEcCtD
Pentoxifylline—Infection—Losartan—type 2 diabetes mellitus	0.000176	0.000624	CcSEcCtD
Pentoxifylline—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000175	0.000624	CcSEcCtD
Pentoxifylline—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000175	0.000623	CcSEcCtD
Pentoxifylline—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000175	0.000623	CcSEcCtD
Pentoxifylline—Tremor—Ramipril—type 2 diabetes mellitus	0.000174	0.000618	CcSEcCtD
Pentoxifylline—Shock—Losartan—type 2 diabetes mellitus	0.000174	0.000618	CcSEcCtD
Pentoxifylline—Urticaria—Valsartan—type 2 diabetes mellitus	0.000174	0.000617	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000173	0.000615	CcSEcCtD
Pentoxifylline—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000173	0.000615	CcSEcCtD
Pentoxifylline—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000173	0.000614	CcSEcCtD
Pentoxifylline—Tachycardia—Losartan—type 2 diabetes mellitus	0.000172	0.000613	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000172	0.000612	CcSEcCtD
Pentoxifylline—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000172	0.000612	CcSEcCtD
Pentoxifylline—Urticaria—Orlistat—type 2 diabetes mellitus	0.000172	0.00061	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000171	0.000608	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000171	0.000607	CcSEcCtD
Pentoxifylline—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000171	0.000607	CcSEcCtD
Pentoxifylline—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000171	0.000607	CcSEcCtD
Pentoxifylline—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000171	0.000607	CcSEcCtD
Pentoxifylline—Agitation—Ramipril—type 2 diabetes mellitus	0.000171	0.000607	CcSEcCtD
Pentoxifylline—Constipation—Metformin—type 2 diabetes mellitus	0.00017	0.000605	CcSEcCtD
Pentoxifylline—Angioedema—Ramipril—type 2 diabetes mellitus	0.00017	0.000603	CcSEcCtD
Pentoxifylline—Anorexia—Losartan—type 2 diabetes mellitus	0.000168	0.000599	CcSEcCtD
Pentoxifylline—Vomiting—Glyburide—type 2 diabetes mellitus	0.000168	0.000599	CcSEcCtD
Pentoxifylline—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000168	0.000598	CcSEcCtD
Pentoxifylline—Malaise—Ramipril—type 2 diabetes mellitus	0.000167	0.000595	CcSEcCtD
Pentoxifylline—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000167	0.000595	CcSEcCtD
Pentoxifylline—Rash—Glyburide—type 2 diabetes mellitus	0.000167	0.000594	CcSEcCtD
Pentoxifylline—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000167	0.000593	CcSEcCtD
Pentoxifylline—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000167	0.000593	CcSEcCtD
Pentoxifylline—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000166	0.000591	CcSEcCtD
Pentoxifylline—Headache—Glyburide—type 2 diabetes mellitus	0.000166	0.00059	CcSEcCtD
Pentoxifylline—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000165	0.000588	CcSEcCtD
Pentoxifylline—Hypotension—Losartan—type 2 diabetes mellitus	0.000165	0.000587	CcSEcCtD
Pentoxifylline—Palpitations—Ramipril—type 2 diabetes mellitus	0.000164	0.000583	CcSEcCtD
Pentoxifylline—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000164	0.000583	CcSEcCtD
Pentoxifylline—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000163	0.00058	CcSEcCtD
Pentoxifylline—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000163	0.000578	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000163	0.000578	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000161	0.000572	CcSEcCtD
Pentoxifylline—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000161	0.000572	CcSEcCtD
Pentoxifylline—Convulsion—Ramipril—type 2 diabetes mellitus	0.000161	0.000572	CcSEcCtD
Pentoxifylline—Constipation—Irbesartan—type 2 diabetes mellitus	0.000161	0.000571	CcSEcCtD
Pentoxifylline—Insomnia—Losartan—type 2 diabetes mellitus	0.00016	0.000568	CcSEcCtD
Pentoxifylline—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000159	0.000565	CcSEcCtD
Pentoxifylline—Urticaria—Metformin—type 2 diabetes mellitus	0.000158	0.000562	CcSEcCtD
Pentoxifylline—Chest pain—Ramipril—type 2 diabetes mellitus	0.000158	0.000562	CcSEcCtD
Pentoxifylline—Myalgia—Ramipril—type 2 diabetes mellitus	0.000158	0.000562	CcSEcCtD
Pentoxifylline—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000158	0.00056	CcSEcCtD
Pentoxifylline—Anxiety—Ramipril—type 2 diabetes mellitus	0.000158	0.00056	CcSEcCtD
Pentoxifylline—Nausea—Glyburide—type 2 diabetes mellitus	0.000157	0.000559	CcSEcCtD
Pentoxifylline—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000157	0.000559	CcSEcCtD
Pentoxifylline—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000157	0.000559	CcSEcCtD
Pentoxifylline—Somnolence—Losartan—type 2 diabetes mellitus	0.000157	0.000558	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000157	0.000558	CcSEcCtD
Pentoxifylline—Asthenia—Valsartan—type 2 diabetes mellitus	0.000157	0.000557	CcSEcCtD
Pentoxifylline—Discomfort—Ramipril—type 2 diabetes mellitus	0.000156	0.000555	CcSEcCtD
Pentoxifylline—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000156	0.000553	CcSEcCtD
Pentoxifylline—Asthenia—Orlistat—type 2 diabetes mellitus	0.000155	0.000551	CcSEcCtD
Pentoxifylline—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000155	0.00055	CcSEcCtD
Pentoxifylline—Pruritus—Valsartan—type 2 diabetes mellitus	0.000155	0.00055	CcSEcCtD
Pentoxifylline—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000155	0.00055	CcSEcCtD
Pentoxifylline—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000154	0.000546	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000154	0.000546	CcSEcCtD
Pentoxifylline—Confusional state—Ramipril—type 2 diabetes mellitus	0.000153	0.000543	CcSEcCtD
Pentoxifylline—Pruritus—Orlistat—type 2 diabetes mellitus	0.000153	0.000543	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000152	0.000539	CcSEcCtD
Pentoxifylline—Oedema—Ramipril—type 2 diabetes mellitus	0.000152	0.000539	CcSEcCtD
Pentoxifylline—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000151	0.000538	CcSEcCtD
Pentoxifylline—Constipation—Losartan—type 2 diabetes mellitus	0.000151	0.000537	CcSEcCtD
Pentoxifylline—Rash—Gliclazide—type 2 diabetes mellitus	0.00015	0.000533	CcSEcCtD
Pentoxifylline—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.00015	0.000533	CcSEcCtD
Pentoxifylline—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00015	0.000531	CcSEcCtD
Pentoxifylline—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000149	0.00053	CcSEcCtD
Pentoxifylline—Shock—Ramipril—type 2 diabetes mellitus	0.000149	0.00053	CcSEcCtD
Pentoxifylline—Headache—Gliclazide—type 2 diabetes mellitus	0.000149	0.00053	CcSEcCtD
Pentoxifylline—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000148	0.000528	CcSEcCtD
Pentoxifylline—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000148	0.000528	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.000148	0.000527	CcSEcCtD
Pentoxifylline—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000148	0.000526	CcSEcCtD
Pentoxifylline—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000148	0.000525	CcSEcCtD
Pentoxifylline—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000147	0.000523	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000147	0.000521	CcSEcCtD
Pentoxifylline—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000146	0.000518	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000145	0.000514	CcSEcCtD
Pentoxifylline—Dizziness—Valsartan—type 2 diabetes mellitus	0.000145	0.000514	CcSEcCtD
Pentoxifylline—Anorexia—Ramipril—type 2 diabetes mellitus	0.000144	0.000513	CcSEcCtD
Pentoxifylline—Dizziness—Orlistat—type 2 diabetes mellitus	0.000143	0.000508	CcSEcCtD
Pentoxifylline—Asthenia—Metformin—type 2 diabetes mellitus	0.000143	0.000507	CcSEcCtD
Pentoxifylline—Hypotension—Ramipril—type 2 diabetes mellitus	0.000142	0.000503	CcSEcCtD
Pentoxifylline—Nausea—Gliclazide—type 2 diabetes mellitus	0.000141	0.000502	CcSEcCtD
Pentoxifylline—Pruritus—Metformin—type 2 diabetes mellitus	0.000141	0.0005	CcSEcCtD
Pentoxifylline—Urticaria—Losartan—type 2 diabetes mellitus	0.00014	0.000499	CcSEcCtD
Pentoxifylline—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00014	0.000497	CcSEcCtD
Pentoxifylline—Body temperature increased—Losartan—type 2 diabetes mellitus	0.00014	0.000497	CcSEcCtD
Pentoxifylline—Vomiting—Valsartan—type 2 diabetes mellitus	0.000139	0.000494	CcSEcCtD
Pentoxifylline—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000138	0.000492	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000138	0.000491	CcSEcCtD
Pentoxifylline—Rash—Valsartan—type 2 diabetes mellitus	0.000138	0.00049	CcSEcCtD
Pentoxifylline—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000138	0.000489	CcSEcCtD
Pentoxifylline—Vomiting—Orlistat—type 2 diabetes mellitus	0.000137	0.000488	CcSEcCtD
Pentoxifylline—Insomnia—Ramipril—type 2 diabetes mellitus	0.000137	0.000487	CcSEcCtD
Pentoxifylline—Headache—Valsartan—type 2 diabetes mellitus	0.000137	0.000487	CcSEcCtD
Pentoxifylline—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000136	0.000484	CcSEcCtD
Pentoxifylline—Rash—Orlistat—type 2 diabetes mellitus	0.000136	0.000484	CcSEcCtD
Pentoxifylline—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000136	0.000483	CcSEcCtD
Pentoxifylline—Headache—Orlistat—type 2 diabetes mellitus	0.000135	0.000481	CcSEcCtD
Pentoxifylline—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000135	0.00048	CcSEcCtD
Pentoxifylline—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000135	0.000479	CcSEcCtD
Pentoxifylline—Somnolence—Ramipril—type 2 diabetes mellitus	0.000135	0.000479	CcSEcCtD
Pentoxifylline—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000133	0.000474	CcSEcCtD
Pentoxifylline—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000133	0.000472	CcSEcCtD
Pentoxifylline—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000132	0.000468	CcSEcCtD
Pentoxifylline—Dizziness—Metformin—type 2 diabetes mellitus	0.000132	0.000468	CcSEcCtD
Pentoxifylline—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00013	0.000463	CcSEcCtD
Pentoxifylline—Nausea—Valsartan—type 2 diabetes mellitus	0.00013	0.000461	CcSEcCtD
Pentoxifylline—Constipation—Ramipril—type 2 diabetes mellitus	0.00013	0.000461	CcSEcCtD
Pentoxifylline—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000128	0.000457	CcSEcCtD
Pentoxifylline—Nausea—Orlistat—type 2 diabetes mellitus	0.000128	0.000456	CcSEcCtD
Pentoxifylline—Asthenia—Losartan—type 2 diabetes mellitus	0.000127	0.000451	CcSEcCtD
Pentoxifylline—Vomiting—Metformin—type 2 diabetes mellitus	0.000127	0.00045	CcSEcCtD
Pentoxifylline—Rash—Metformin—type 2 diabetes mellitus	0.000125	0.000446	CcSEcCtD
Pentoxifylline—Dermatitis—Metformin—type 2 diabetes mellitus	0.000125	0.000446	CcSEcCtD
Pentoxifylline—Pruritus—Losartan—type 2 diabetes mellitus	0.000125	0.000444	CcSEcCtD
Pentoxifylline—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000125	0.000444	CcSEcCtD
Pentoxifylline—Headache—Metformin—type 2 diabetes mellitus	0.000125	0.000443	CcSEcCtD
Pentoxifylline—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000124	0.000441	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000124	0.00044	CcSEcCtD
Pentoxifylline—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000121	0.00043	CcSEcCtD
Pentoxifylline—Urticaria—Ramipril—type 2 diabetes mellitus	0.00012	0.000428	CcSEcCtD
Pentoxifylline—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.00012	0.000426	CcSEcCtD
Pentoxifylline—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.00012	0.000426	CcSEcCtD
Pentoxifylline—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000119	0.000424	CcSEcCtD
Pentoxifylline—Rash—Irbesartan—type 2 diabetes mellitus	0.000118	0.000421	CcSEcCtD
Pentoxifylline—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000118	0.00042	CcSEcCtD
Pentoxifylline—Nausea—Metformin—type 2 diabetes mellitus	0.000118	0.00042	CcSEcCtD
Pentoxifylline—Headache—Irbesartan—type 2 diabetes mellitus	0.000118	0.000418	CcSEcCtD
Pentoxifylline—Dizziness—Losartan—type 2 diabetes mellitus	0.000117	0.000415	CcSEcCtD
Pentoxifylline—Vomiting—Losartan—type 2 diabetes mellitus	0.000112	0.000399	CcSEcCtD
Pentoxifylline—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000112	0.000397	CcSEcCtD
Pentoxifylline—Nausea—Irbesartan—type 2 diabetes mellitus	0.000112	0.000396	CcSEcCtD
Pentoxifylline—Rash—Losartan—type 2 diabetes mellitus	0.000111	0.000396	CcSEcCtD
Pentoxifylline—Dermatitis—Losartan—type 2 diabetes mellitus	0.000111	0.000396	CcSEcCtD
Pentoxifylline—Headache—Losartan—type 2 diabetes mellitus	0.000111	0.000394	CcSEcCtD
Pentoxifylline—Asthenia—Ramipril—type 2 diabetes mellitus	0.000109	0.000386	CcSEcCtD
Pentoxifylline—Pruritus—Ramipril—type 2 diabetes mellitus	0.000107	0.000381	CcSEcCtD
Pentoxifylline—Nausea—Losartan—type 2 diabetes mellitus	0.000105	0.000373	CcSEcCtD
Pentoxifylline—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000104	0.000369	CcSEcCtD
Pentoxifylline—Dizziness—Ramipril—type 2 diabetes mellitus	0.0001	0.000356	CcSEcCtD
Pentoxifylline—Vomiting—Ramipril—type 2 diabetes mellitus	9.64e-05	0.000342	CcSEcCtD
Pentoxifylline—Rash—Ramipril—type 2 diabetes mellitus	9.56e-05	0.00034	CcSEcCtD
Pentoxifylline—Dermatitis—Ramipril—type 2 diabetes mellitus	9.55e-05	0.000339	CcSEcCtD
Pentoxifylline—Headache—Ramipril—type 2 diabetes mellitus	9.49e-05	0.000337	CcSEcCtD
Pentoxifylline—Nausea—Ramipril—type 2 diabetes mellitus	9e-05	0.00032	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.81e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.81e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—C3—type 2 diabetes mellitus	1.8e-05	0.000116	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.8e-05	0.000115	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.79e-05	0.000115	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.79e-05	0.000115	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—C3—type 2 diabetes mellitus	1.78e-05	0.000114	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.77e-05	0.000114	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.76e-05	0.000113	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.72e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.71e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.71e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AGT—type 2 diabetes mellitus	1.71e-05	0.00011	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MAT1A—type 2 diabetes mellitus	1.7e-05	0.000109	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC5A4—type 2 diabetes mellitus	1.7e-05	0.000109	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.7e-05	0.000109	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.7e-05	0.000109	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.69e-05	0.000109	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—SREBF1—type 2 diabetes mellitus	1.69e-05	0.000109	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AGT—type 2 diabetes mellitus	1.69e-05	0.000108	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.69e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—INS—type 2 diabetes mellitus	1.69e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.68e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—APOE—type 2 diabetes mellitus	1.68e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—LEP—type 2 diabetes mellitus	1.68e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.67e-05	0.000107	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.67e-05	0.000107	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.67e-05	0.000107	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.66e-05	0.000107	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—type 2 diabetes mellitus	1.66e-05	0.000107	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.66e-05	0.000106	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.66e-05	0.000106	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.66e-05	0.000106	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—LEP—type 2 diabetes mellitus	1.66e-05	0.000106	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—APOE—type 2 diabetes mellitus	1.66e-05	0.000106	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—type 2 diabetes mellitus	1.65e-05	0.000106	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—G6PC—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HBA2—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ND1—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ENPP1—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.64e-05	0.000105	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.63e-05	0.000105	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.63e-05	0.000104	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.62e-05	0.000104	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	1.62e-05	0.000104	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.61e-05	0.000103	CbGpPWpGaD
Pentoxifylline—NT5E—Metabolism—AKT1—type 2 diabetes mellitus	1.61e-05	0.000103	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.6e-05	0.000102	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.59e-05	0.000102	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GCGR—type 2 diabetes mellitus	1.59e-05	0.000102	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.58e-05	0.000101	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.56e-05	0.0001	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.55e-05	9.93e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	1.54e-05	9.91e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—INS—type 2 diabetes mellitus	1.53e-05	9.81e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.51e-05	9.7e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.51e-05	9.66e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—OXCT1—type 2 diabetes mellitus	1.5e-05	9.63e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYTB—type 2 diabetes mellitus	1.5e-05	9.63e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.5e-05	9.6e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.48e-05	9.49e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.48e-05	9.49e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.48e-05	9.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.48e-05	9.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.48e-05	9.48e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.47e-05	9.45e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SRD5A1—type 2 diabetes mellitus	1.46e-05	9.38e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.45e-05	9.3e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—INS—type 2 diabetes mellitus	1.43e-05	9.19e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.42e-05	9.13e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—INS—type 2 diabetes mellitus	1.42e-05	9.08e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.41e-05	9.04e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.41e-05	9.01e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—STAR—type 2 diabetes mellitus	1.4e-05	8.95e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSD17B3—type 2 diabetes mellitus	1.4e-05	8.95e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ACACA—type 2 diabetes mellitus	1.4e-05	8.95e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.39e-05	8.93e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.39e-05	8.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.39e-05	8.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.39e-05	8.89e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.38e-05	8.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.38e-05	8.84e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.37e-05	8.78e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.37e-05	8.78e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.36e-05	8.74e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.34e-05	8.61e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.34e-05	8.61e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCC8—type 2 diabetes mellitus	1.34e-05	8.58e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CBS—type 2 diabetes mellitus	1.34e-05	8.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.33e-05	8.51e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.32e-05	8.49e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.32e-05	8.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.32e-05	8.44e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.3e-05	8.34e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.3e-05	8.33e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.29e-05	8.31e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.29e-05	8.31e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—COX2—type 2 diabetes mellitus	1.29e-05	8.26e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC5A2—type 2 diabetes mellitus	1.29e-05	8.26e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.28e-05	8.21e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.27e-05	8.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NCOA6—type 2 diabetes mellitus	1.27e-05	8.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	1.26e-05	8.11e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.26e-05	8.1e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.26e-05	8.06e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.26e-05	8.06e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.25e-05	8.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.25e-05	7.99e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—UCP2—type 2 diabetes mellitus	1.24e-05	7.98e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—UCP3—type 2 diabetes mellitus	1.24e-05	7.98e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSD11B1—type 2 diabetes mellitus	1.24e-05	7.98e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.24e-05	7.96e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.24e-05	7.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.22e-05	7.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	1.21e-05	7.73e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.19e-05	7.6e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.18e-05	7.59e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.17e-05	7.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PCK1—type 2 diabetes mellitus	1.17e-05	7.5e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.17e-05	7.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.16e-05	7.41e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.15e-05	7.38e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.15e-05	7.38e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.15e-05	7.37e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.14e-05	7.31e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.13e-05	7.26e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1.12e-05	7.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.11e-05	7.1e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HK1—type 2 diabetes mellitus	1.1e-05	7.02e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	1.09e-05	7.02e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.09e-05	7.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.09e-05	6.98e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.08e-05	6.91e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.08e-05	6.9e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.07e-05	6.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.07e-05	6.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.07e-05	6.84e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.07e-05	6.83e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.06e-05	6.83e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.06e-05	6.83e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.06e-05	6.82e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.06e-05	6.8e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GCKR—type 2 diabetes mellitus	1.06e-05	6.78e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HSD3B2—type 2 diabetes mellitus	1.06e-05	6.78e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—KCNJ11—type 2 diabetes mellitus	1.06e-05	6.78e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPA—type 2 diabetes mellitus	1.06e-05	6.78e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.05e-05	6.76e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.05e-05	6.72e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.04e-05	6.7e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	1.02e-05	6.52e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.02e-05	6.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALDOB—type 2 diabetes mellitus	1.01e-05	6.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.01e-05	6.47e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.97e-06	6.4e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.96e-06	6.39e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.93e-06	6.37e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.86e-06	6.32e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	9.85e-06	6.32e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.78e-06	6.27e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.77e-06	6.27e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	9.7e-06	6.22e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	9.7e-06	6.22e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.67e-06	6.2e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.66e-06	6.2e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	9.65e-06	6.19e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.58e-06	6.14e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	9.54e-06	6.12e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	9.43e-06	6.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—SRC—type 2 diabetes mellitus	9.29e-06	5.96e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—SRC—type 2 diabetes mellitus	9.18e-06	5.89e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	9.13e-06	5.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	9.05e-06	5.81e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.94e-06	5.74e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.87e-06	5.69e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	8.8e-06	5.64e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.7e-06	5.58e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	8.62e-06	5.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	8.62e-06	5.53e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	8.46e-06	5.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	8.41e-06	5.39e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	8.4e-06	5.39e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	8.4e-06	5.39e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	8.4e-06	5.39e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	8.35e-06	5.36e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	8.31e-06	5.33e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.31e-06	5.33e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.24e-06	5.28e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.21e-06	5.27e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	8.2e-06	5.26e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.18e-06	5.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.15e-06	5.22e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	8.11e-06	5.2e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.05e-06	5.16e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.78e-06	4.99e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.7e-06	4.94e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	7.56e-06	4.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.55e-06	4.84e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	7.54e-06	4.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	7.54e-06	4.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	7.54e-06	4.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	7.4e-06	4.74e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	7.36e-06	4.72e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	7.33e-06	4.7e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	7.23e-06	4.64e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	7.18e-06	4.6e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	7.17e-06	4.6e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.99e-06	4.48e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	6.89e-06	4.42e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	6.82e-06	4.37e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.79e-06	4.36e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.69e-06	4.29e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	6.65e-06	4.26e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	6.61e-06	4.24e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	6.53e-06	4.19e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	6.53e-06	4.19e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.41e-06	4.11e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.29e-06	4.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—type 2 diabetes mellitus	6.26e-06	4.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—type 2 diabetes mellitus	6.19e-06	3.97e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.17e-06	3.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.78e-06	3.7e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.71e-06	3.66e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	5.63e-06	3.61e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.63e-06	3.61e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	5.61e-06	3.6e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	5.53e-06	3.55e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	5.37e-06	3.44e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	5.22e-06	3.35e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	5.13e-06	3.29e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	5.02e-06	3.22e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	5e-06	3.21e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	4.87e-06	3.12e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	4.83e-06	3.1e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	4.81e-06	3.09e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	4.62e-06	2.96e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	4.53e-06	2.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.46e-06	2.86e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	4.39e-06	2.81e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	4.31e-06	2.77e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	4.3e-06	2.76e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	4.25e-06	2.73e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	3.74e-06	2.4e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	3.67e-06	2.36e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	3.37e-06	2.16e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.22e-06	2.07e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	3.22e-06	2.07e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	2.94e-06	1.89e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.48e-06	9.49e-06	CbGpPWpGaD
